De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

INKON Life Technology Toekomstige groei

Future criteriumcontroles 4/6

INKON Life Technology zal naar verwachting groeien in winst en omzet met respectievelijk 32.4% en 15.6% per jaar. De winst per aandeel zal naar verwachting groeien met 32.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10.1% zijn.

Belangrijke informatie

32.4%

Groei van de winst

32.3%

Groei van de winst per aandeel

Healthcare winstgroei	21.2%
Inkomstengroei	15.6%
Toekomstig rendement op eigen vermogen	10.1%
Dekking van analisten	Low
Laatst bijgewerkt	26 Aug 2024

Recente toekomstige groei-updates

INKON Life Technology Co., Ltd. Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

Apr 23

Recent updates

INKON Life Technology Co., Ltd. (SZSE:300143) Looks Just Right With A 26% Price Jump

Sep 30

Returns Are Gaining Momentum At INKON Life Technology (SZSE:300143)

Sep 29

INKON Life Technology (SZSE:300143) Seems To Use Debt Quite Sensibly

Sep 10

INKON Life Technology Co., Ltd. Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

Apr 23

What You Can Learn From INKON Life Technology Co., Ltd.'s (SZSE:300143) P/S

Mar 28

Winst- en omzetgroeiprognoses

SZSE:300143 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2,333	209	N/A	308	2
12/31/2025	2,039	165	N/A	264	2
12/31/2024	1,754	126	N/A	304	2
6/30/2024	1,570	85	132	299	N/A
3/31/2024	1,526	87	107	254	N/A
12/31/2023	1,471	100	32	190	N/A
9/30/2023	1,396	-557	51	244	N/A
6/30/2023	1,305	-573	92	239	N/A
3/31/2023	1,250	-580	15	163	N/A
1/1/2023	1,156	-596	35	161	N/A
9/30/2022	1,106	-436	28	98	N/A
6/30/2022	1,129	-358	7	55	N/A
3/31/2022	1,116	-358	52	104	N/A
1/1/2022	1,090	-364	69	126	N/A
9/30/2021	1,388	233	63	133	N/A
6/30/2021	1,281	163	90	158	N/A
3/31/2021	1,170	179	34	108	N/A
12/31/2020	1,029	149	22	85	N/A
9/30/2020	659	-700	28	69	N/A
6/30/2020	602	-700	2	38	N/A
3/31/2020	567	-716	55	79	N/A
12/31/2019	573	-703	3	30	N/A
9/30/2019	520	21	24	54	N/A
6/30/2019	508	28	66	99	N/A
3/31/2019	467	15	70	97	N/A
12/31/2018	504	50	74	100	N/A
9/30/2018	471	64	89	154	N/A
6/30/2018	451	87	70	132	N/A
3/31/2018	433	107	N/A	152	N/A
12/31/2017	329	122	N/A	167	N/A
9/30/2017	381	150	N/A	198	N/A
6/30/2017	388	122	N/A	118	N/A
3/31/2017	390	98	N/A	50	N/A
12/31/2016	432	55	N/A	45	N/A
9/30/2016	377	32	N/A	-25	N/A
6/30/2016	329	18	N/A	25	N/A
3/31/2016	290	17	N/A	39	N/A
12/31/2015	280	11	N/A	52	N/A
9/30/2015	289	-253	N/A	44	N/A
6/30/2015	297	-272	N/A	29	N/A
3/31/2015	300	-294	N/A	19	N/A
12/31/2014	308	-293	N/A	21	N/A
9/30/2014	297	-135	N/A	18	N/A
6/30/2014	287	-132	N/A	23	N/A
3/31/2014	274	-147	N/A	29	N/A
12/31/2013	255	-163	N/A	14	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 300143 ( 32.4% per jaar) ligt boven de spaarquote ( 2.9% ).

Winst versus markt: De winst van 300143 ( 32.4% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 23.2% per jaar).

Hoge groeiwinsten: De winst van 300143 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 300143 ( 15.6% per jaar) zal naar verwachting sneller groeien dan de markt CN ( 13.2% per jaar).

Hoge groei-inkomsten: De omzet van 300143 ( 15.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 300143 zal naar verwachting over 3 jaar laag zijn ( 10.1 %).

INKON Life Technology Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

INKON Life Technology Co., Ltd. Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

Price target decreased by 7.9% to CN¥12.27

Price target decreased to CN¥14.25

Price target decreased to CN¥22.88

Price target decreased to CN¥21.84

Recent updates

INKON Life Technology Co., Ltd. (SZSE:300143) Looks Just Right With A 26% Price Jump

INKON Life Technology Co., Ltd. to Report Q3, 2024 Results on Oct 28, 2024

Investor sentiment improves as stock rises 32%

Returns Are Gaining Momentum At INKON Life Technology (SZSE:300143)

Now 23% undervalued

INKON Life Technology (SZSE:300143) Seems To Use Debt Quite Sensibly

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.045 (vs CN¥0.057 in 2Q 2023)

Investor sentiment improves as stock rises 15%

INKON Life Technology Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

INKON Life Technology Co., Ltd. Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

INKON Life Technology Co., Ltd., Annual General Meeting, May 13, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

INKON Life Technology Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

What You Can Learn From INKON Life Technology Co., Ltd.'s (SZSE:300143) P/S

Price target decreased by 7.9% to CN¥12.27

INKON Life Technology Co., Ltd. (SZSE:300143) announces an Equity Buyback for CNY 80 million worth of its shares.

INKON Life Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.013 in 3Q 2022)

Now 21% undervalued after recent price drop

Inkon Life Technology Co., Ltd. Announces Directorate Appointments

INKON Life Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.057 (vs CN¥0.036 in 2Q 2022)

Full year 2022 earnings released: CN¥1.01 loss per share (vs CN¥0.57 loss in FY 2021)

Price target decreased to CN¥14.25

High number of new directors

High number of new directors

Qingdao Haiyingkang Investment Co., Ltd. and INKON Life Technology Co., Ltd. (SZSE:300143) agreed to acquire Shenzhen Shengzhong Investment Enterprise (Limited Partnership) from a group of shareholders for CNY 87.7 million.

Third quarter 2022 earnings released: EPS: CN¥0.013 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.036 (vs CN¥0.019 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥22.88

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.026 in 3Q 2020)

Qingdao Yingkang Medical Investment Co., Ltd. acquired Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. (SZSE:300143) for CNY 1.3 million.

Price target decreased to CN¥21.84

Second quarter 2021 earnings released: EPS CN¥0.019 (vs CN¥0.071 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.018 (vs CN¥0.021 loss in 1Q 2020)

INKON Life Technology Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥18.00

New 90-day low: CN¥20.30

New 90-day low: CN¥21.84

New 90-day low: CN¥22.19

Third quarter earnings released

First half earnings released

New 90-day high - CN¥25.53

INKON Life Technology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

INKON Life Technology Co., Ltd. announced that it has received CNY 732.939997 million in funding from Qingdao Yingkang Medical Investment Co., Ltd.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven